Psych · General adult psychiatry — psychosis
Negative and cognitive symptoms of schizophrenia
Also known as Deficit syndrome · Primary negative symptoms · Secondary negative symptoms · Avolition-apathy · Diminished expression · Schizophrenia neurocognition · MATRICS cognitive domains
Exam-exhaustive fellowship reference on negative and cognitive symptoms of schizophrenia — primary versus secondary negatives, deficit syndrome, SANS/PANSS and NIMH domains, MATRICS cognition, functional outcome, limited pharmacotherapy evidence with careful cariprazine and clozapine nuance, cognitive remediation, and psychosocial rehabilitation. FRANZCP-primary, globally tagged.
Practise this topic
On this page
Study tools
Your progress
Saved on this device.
Target exams
Red flags
- Severe self-neglect, dehydration, or inability to self-care under 'negative symptoms' — escalate setting; this is medical and psychiatric risk, not laziness
- Suicidal ideation under blunted affect — flat affect does not equal absence of distress; reassess suicide risk explicitly
- New or progressive cognitive decline, seizures, or focal neurology — do not assume chronic schizophrenia residual; investigate organic causes
- Parkinsonism, oversedation, or untreated depression labelled as 'primary negatives' — secondary causes first
- Catatonia or NMS misread as extreme blunting/avolition — emergency pathway
- Stacking high-dose antipsychotics for primary negatives without fixing secondary causes or offering rehabilitation
Meet the patient
A 34-year-old man has been "stable" for four years. No voices, no delusions, no admissions. He sleeps until midday, has not seen a friend since 2021, sits in one chair, and answers every question with three words.[2][3]
His mother says he has become lazy. The ward round says he is doing well. He is on risperidone 6 mg, he blinks rarely, and his arms do not swing when he walks.[11][18]
Nobody in the room has asked whether the flatness is the illness or the prescription. That question is this entire topic.[2][11]
References18ShowHide
- [1]Kirkpatrick B, Fenton WS, Carpenter WT Jr, et al. The NIMH-MATRICS consensus statement on negative symptoms Schizophr Bull, 2006.PMID 16481659
- [2]Marder SR, Galderisi S The current conceptualization of negative symptoms in schizophrenia World Psychiatry, 2017.PMID 28127915
- [3]Galderisi S, Mucci A, Buchanan RW, et al. Negative symptoms of schizophrenia: new developments and unanswered research questions Lancet Psychiatry, 2018.PMID 29602739
- [4]Carpenter WT Jr, Heinrichs DW, Wagman AM Deficit and nondeficit forms of schizophrenia: the concept Am J Psychiatry, 1988.PMID 3358462
- [5]Andreasen NC The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations Br J Psychiatry Suppl, 1989.PMID 2695141
- [6]Kay SR, Fiszbein A, Opler LA The positive and negative syndrome scale (PANSS) for schizophrenia Schizophr Bull, 1987.PMID 3616518
- [7]Blanchard JJ, Cohen AS The structure of negative symptoms within schizophrenia: implications for assessment Schizophr Bull, 2006.PMID 16254064
- [8]Strauss GP, Horan WP, Kirkpatrick B, et al. Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome J Psychiatr Res, 2013.PMID 23453820
- [9]Green MF What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry, 1996.PMID 8610818
- [10]Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity Am J Psychiatry, 2008.PMID 18172019
- [11]Fusar-Poli P, Papanastasiou E, Stahl D, et al. Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials Schizophr Bull, 2015.PMID 25528757
- [12]Németh G, Laszlovszky I, Czobor P, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial Lancet, 2017.PMID 28185672
- [13]Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine Arch Gen Psychiatry, 1988.PMID 3046553
- [14]Wykes T, Huddy V, Cellard C, et al. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes Am J Psychiatry, 2011.PMID 21406461
- [15]Vita A, Barlati S, Ceraso A, et al. Effectiveness, Core Elements, and Moderators of Response of Cognitive Remediation for Schizophrenia: A Systematic Review and Meta-analysis of Randomized Clinical Trials JAMA Psychiatry, 2021.PMID 33877289
- [16]Galletly C, Castle D, Dark F, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders Aust N Z J Psychiatry, 2016.PMID 27106681
- [17]Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia Am J Psychiatry, 2020.PMID 32867516
- [18]Howes OD, Kapur S The dopamine hypothesis of schizophrenia: version III--the final common pathway Schizophr Bull, 2009.PMID 19325164